

AERIE PHARMACEUTICALS INC  
Form SC 13D/A  
May 30, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS  
THERE TO FILED PURSUANT TO 13d-2(a)

(Amendment # 1)\*

(Name of Issuer) Aerie Pharmaceuticals, Inc.

(Title of Class of Securities) Common Stock, par value \$0.001 per share

(CUSIP Number) 0771V108

Larry Randall  
Alta Partners  
One Embarcadero Center, Suite 3700  
San Francisco, CA 94111  
(415) 362-4022  
(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

May 22, 2014  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. o

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP # 0771V108

13D

1. Names of Reporting Persons.

ACP IV, L.P.

2. Check The Appropriate Box If A Member Of A Group

(a) o

(b) x

3. SEC USE ONLY

4. Source of Funds

WC

5. Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items 2(d) Or 2(e):

o

6. Citizenship or Place of Organization

Delaware

7. Sole Voting Power

3,989,582 (a)

Number of  
Shares

8. Shared Voting Power

Beneficially

-0-

Owned by

9. Sole Dispositive Power

Each

Reporting

Person with

10. Shared Dispositive Power

-0-

11. Aggregate Amount Beneficially Owned by Each Reporting Person

3,989,582 (a)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares\*

o

13. Percent of Class Represented by Amount in Row (11)

16.8% (b)

14. Type of Reporting Person

PN

(a) Includes (i) 3,616,099 shares of Common Stock and (ii) warrants to purchase 373,483 shares of Common Stock held by ACP IV, L.P. ("ACP"). ACP has sole voting and dispositive control over these shares of common stock ("Common Stock") of Aerie Pharmaceuticals, Inc. (the "Issuer"), except that ACMP IV, LLC ("ACMP"), the general partner

of ACP, and Daniel S. Janney (“Janney”) and Guy P. Nohra (“Nohra” and collectively with Janney, the “Directors”), directors of ACMP, may be deemed to share the right to direct the voting and dispositive control over such stock. ACP, ACMP and the Directors are sometimes collectively referred to herein as the “Reporting Persons.”

(b) This percentage is based upon (i) 23,437,055 shares of the Issuer’s Common Stock outstanding as of May 6, 2014 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on May 13, 2014, plus (ii) 373,483 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons within 60 days of the date of this filing.

CUSIP # 0771V108

13D

1. Names of Reporting Persons.

ACMP IV, LLC

2. Check The Appropriate Box If A Member Of A Group

(a) o

(b) x

3. SEC USE ONLY

4. Source of Funds

WC

5. Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items 2(d) Or 2(e):

o

6. Citizenship or Place of Organization

Delaware

7. Sole Voting Power

3,989,582 (c)

Number of  
Shares

8. Shared Voting Power

Beneficially

-0-

Owned by

9. Sole Dispositive Power

Each

Reporting

Person with

10. Shared Dispositive Power

-0-

11. Aggregate Amount Beneficially Owned by Each Reporting Person

3,989,582 (c)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares\*

o

13. Percent of Class Represented by Amount in Row (11)

16.8% (b)

14. Type of Reporting Person

OO

(c) Includes (i) 3,616,099 shares of Common Stock and (ii) warrants to purchase 373,483 shares of Common Stock held by ACP. ACP has sole voting and dispositive control over these shares of Common Stock, except that ACMP, as the general partner of ACP, and Janney and Nohra, as directors of ACMP, may be deemed to share the right to direct

the voting and dispositive control over such stock.

(b) This percentage is based upon (i) 23,437,055 shares of the Issuer's Common Stock outstanding as of May 6, 2014 as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on May 13, 2014, plus (ii) 373,483 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons within 60 days of the date of this filing.

CUSIP # 0771V108

13D

1. Names of Reporting Persons.

Daniel S. Janney

2. Check The Appropriate Box If A Member Of A Group

(a) o

(b) x

3. SEC USE ONLY

4. Source of Funds

WC

5. Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items 2(d) Or 2(e):

o

6. Citizenship or Place of Organization

United States of America

7.

Sole Voting Power

Number of  
Shares

8.

-0-

Shared Voting Power

Beneficially

Owned by

9.

3,989,582 (c)

Sole Dispositive Power

Each

Reporting

Person with

10.

-0-

Shared Dispositive Power

3,989,582 (c)

11. Aggregate Amount Beneficially Owned by Each Reporting Person

3,989,582 (c)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares\*

o

13. Percent of Class Represented by Amount in Row (11)

16.8% (b)

14. Type of Reporting Person

IN

(c) Includes (i) 3,616,099 shares of Common Stock and (ii) warrants to purchase 373,483 shares of Common Stock held by ACP. ACP has sole voting and dispositive control over these shares of Common Stock, except that ACMP, as the general partner of ACP, and Janney and Nohra, as directors of ACMP, may be deemed to share the right to direct

the voting and dispositive control over such stock.

(b) This percentage is based upon (i) 23,437,055 shares of the Issuer's Common Stock outstanding as of May 6, 2014 as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on May 13, 2014, plus (ii) 373,483 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons within 60 days of the date of this filing.



CUSIP # 0771V108

13D

1. Names of Reporting Persons.

Guy P. Nohra

2. Check The Appropriate Box If A Member Of A Group

(a) o

(b) x

3. SEC USE ONLY

4. Source of Funds

WC

5. Box If Disclosure Of Legal Proceedings Is Required Pursuant To Items 2(d) Or 2(e):

o

6. Citizenship or Place of Organization

United States of America

7.

Sole Voting Power

Number of  
Shares

8.

-0-

Shared Voting Power

Beneficially

Owned by

9.

3,989,582 (c)

Sole Dispositive Power

Each

Reporting

Person with

10.

-0-

Shared Dispositive Power

3,989,582 (c)

11. Aggregate Amount Beneficially Owned by Each Reporting Person

3,989,582 (c)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares\*

o

13. Percent of Class Represented by Amount in Row (11)

16.8% (b)

14. Type of Reporting Person

IN

(c) Includes (i) 3,616,099 shares of Common Stock and (ii) warrants to purchase 373,483 shares of Common Stock held by ACP. ACP has sole voting and dispositive control over these shares of Common Stock, except that ACMP, as the general partner of ACP, and Janney and Nohra, as directors of ACMP, may be deemed to share the right to direct

the voting and dispositive control over such stock..

(b) This percentage is based upon (i) 23,437,055 shares of the Issuer's Common Stock outstanding as of May 6, 2014 as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on May 13, 2014, plus (ii) 373,483 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons within 60 days of the date of this filing.

CUSIP # 0771V108

13D

## Explanatory Note.

This Amendment No. 1 to Schedule 13D (this “Schedule 13D/A”) is being filed to amend the statement on Schedule 13D relating to the common stock, par value \$0.001 per share (the “Common Stock”), of Aerie Pharmaceuticals Inc., a Delaware corporation (the “Issuer”), as initially filed with the Securities and Exchange Commission on November 12, 2013 (the “Original Schedule 13D”). This Schedule 13D/A is being filed to report sales of Common Stock by the Reporting Persons in an open market transaction on May 22, 2014. The Original Schedule 13D is hereby amended and supplemented as detailed below and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms not otherwise defined herein shall have the meaning ascribed to the terms in the Original Schedule 13D.

## Item 4. Purpose of Transaction.

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

On May 22, 2014, ACP sold an aggregate of 300,000 shares of Common Stock in an open market transaction at \$16.00 per share.

## Item 5. Interest in Securities of the Issuer.

Items 5(a), 5(b), and 5(c) of the Original Schedule 13D are hereby amended and restated in their entirety to read as follows:

(a)-(b)

Reporting Person	Shares Held Directly	Sole Voting Power	Shared Voting Power (2)	Sole Dispositive Power	Shared Dispositive Power (2)	Beneficial Ownership	Percentage of Class
ACP IV, L.P.	3,989,582 (1)	3,989,582 (1)	0	3,989,582 (1)	0	3,989,582	16.8% (3)
ACMP LLV 0		0	3,989,582	0	3,989,582	3,989,582	16.8% (3)
Daniel S. Janney	0	0	3,989,582	0	3,989,582	3,989,582	16.8% (3)
Guy P. Nohra	0	0	3,989,582	0	3,989,582	3,989,582	16.8% (3)

(1) Includes (i) 3,616,099 shares of Common Stock and (ii) warrants to purchase 373,483 shares of Common Stock held by ACP.

(2) Janney and Nohra serve as directors of ACMP, which serves as the general partner of ACP. ACMP owns no securities of the Issuer directly. Janney and Nohra share voting and investment control over the shares owned by ACP and may be deemed to beneficially own the shares held by ACP.

(3) This percentage is based upon (i) 23,437,055 shares of the Issuer’s Common Stock outstanding as of May 6, 2014 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on May 13, 2014, plus (ii)

Edgar Filing: AERIE PHARMACEUTICALS INC - Form SC 13D/A

373,483 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons within 60 days of the date of this filing.

(c) On May 22, 2014, ACP sold an aggregate of 300,000 shares of Common Stock in an open market transaction at \$16.00 per share.

Item 7. Material to be Filed as Exhibits.

Exhibit A: Joint Filing Statement.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 30, 2014

ACP IV, L.P.

By: ACMP IV, LLC

By: /s/ Larry Randall

Name: Larry Randall

Title: CFO

ACMP IV, LLC

By: /s/ Larry Randall

Name: Larry Randall

Title: CFO

/s/ Daniel S.

Janney

Daniel S. Janney

/s/ Guy P. Nohra

Guy P. Nohra

EXHIBIT A

Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us.

Date: May 30, 2014

ACP IV, L.P.

By: ACMP IV, LLC

By: /s/ Larry Randall

Name: Larry Randall

Title: CFO

ACMP IV, LLC

By: /s/ Larry Randall

Name: Larry Randall

Title: CFO

/s/ Daniel S.

Janney

Daniel S. Janney

/s/ Guy P. Nohra

Guy P. Nohra